Actelion is part of the Johnson & Johnson Family of Companies. We are the recognized global leader in pulmonary arterial hypertension, a serious condition affecting the pulmonary arteries and the right side of the heart, which must pump blood to the lungs against increased resistance. Our understanding of the complex pathways and molecular mechanisms of this disease has enabled us to develop tailored medicines to improve patient outcomes and make a difference for people around the world living with this disorder.
As one of the Janssen Pharmaceutical Companies of Johnson & Johnson, we will maintain our leadership position in this space. Janssen has established Pulmonary Hypertension (PH) as a sixth therapeutic area (TA) of focus, complementing its current TAs in Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience and Oncology. We are excited to continue our 20-year legacy of ground-breaking innovation in this important disease area.
We also have treatments for other serious illnesses including type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell lymphoma.
Through Janssen’s science and patient focus, and geographic and commercial reach, we look forward to bringing our in-market medicines to even more patients who need them around the world and accelerating market entry for our promising late-stage development assets.
Find out more about our groundbreaking therapies.
Find out more about the new therapies we are developing.
Find out more about how Actelion became the leaders in PAH.
Find out more about the values that drive us.